Launched in 2010, the Singapore-Stanford Biodesign (SSB) Programme is a joint partnership between the Agency for Science, Technology and Research (A*STAR), the Economic Development Board (EDB) and Stanford University.
Modelled after the established Biodesign Programme at Stanford University, this capability development initiative aims to train and nurture the next generation of medical technology innovators for Singapore and Asia.
Since 5 December 2019, SSB has been re-named as Singapore Biodesign, signifying a move to being more Asia and implementation focussed to bring about economic benefits and healthcare value through healthtech innovation training.
Mission: High-touch development of healthtech talent centered on needs-based approach and quality industry mentoring to accelerate health technology innovation and adoption for Asia's* unmet healthcare needs.
Vision: To be Asia's leading HealthTech talent development and knowledge partner for accelerating health technologies innovation towards commercialization and adoption.